{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:00:29Z","timestamp":1778778029949,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005117","name":"Birjand University of Medical Sciences","doi-asserted-by":"publisher","award":["5653"],"award-info":[{"award-number":["5653"]}],"id":[{"id":"10.13039\/501100005117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.intimp.2021.108351","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:30:16Z","timestamp":1636504216000},"page":"108351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"PB","title":["Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran"],"prefix":"10.1016","volume":"101","author":[{"given":"Hamed","family":"Zare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadis","family":"Rezapour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mahmoodzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Fereidouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10240","key":"10.1016\/j.intimp.2021.108351_b0005","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"The Lancet"},{"issue":"10249","key":"10.1016\/j.intimp.2021.108351_b0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2021.108351_b0015","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.ijtb.2020.09.031","article-title":"Morbidity and mortality trends of Covid 19 in top 10 countries","volume":"67","author":"Matta","year":"2020","journal-title":"Ind. J. Tubercul."},{"issue":"8","key":"10.1016\/j.intimp.2021.108351_b0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10249","key":"10.1016\/j.intimp.2021.108351_b0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2021.108351_b0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.dsx.2020.12.025","article-title":"Long COVID-19: Challenges in the diagnosis and proposed diagnostic criteria","volume":"15","author":"Raveendran","year":"2021","journal-title":"Diab. & Metab. Synd."},{"key":"10.1016\/j.intimp.2021.108351_b0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3389\/fmed.2021.653516","article-title":"Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. a systematic review of the current data","volume":"8","author":"Salamanna","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2021.108351_b0040","doi-asserted-by":"crossref","unstructured":"A. Parkin, J. Davison, R. Tarrant, D. Ross, S. Halpin, A. Simms, R. Salman, M. Sivan, A Multidisciplinary NHS COVID-19 Service to Manage Post-COVID-19 Syndrome in the Community, Journal of Primary Care & Community Health 12 (2021) 21501327211010994.","DOI":"10.1177\/21501327211010994"},{"issue":"25","key":"10.1016\/j.intimp.2021.108351_b0045","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2021.108351_b0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2021.108351_b0055","first-page":"39","article-title":"Forecasting wave-like patterns of COVID-19 daily infected cases in Iran","volume":"2","author":"Konarasinghe","year":"2021","journal-title":"J. New Front. Healthcare Biol. Sci."},{"issue":"23","key":"10.1016\/j.intimp.2021.108351_b0060","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.79.23.7415","article-title":"Vaccinia virus: a selectable eukaryotic cloning and expression vector","volume":"79","author":"Mackett","year":"1982","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2021.108351_b0065","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1073\/pnas.69.10.2904","article-title":"Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli","volume":"69","author":"Jackson","year":"1972","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2021.108351_b0070","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ijbiomac.2021.08.076","article-title":"SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: a review","volume":"188","author":"Fathizadeh","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"10","key":"10.1016\/j.intimp.2021.108351_b0075","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.intimp.2021.108351_b0080","first-page":"E115","article-title":"History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines","volume":"57","author":"Barberis","year":"2016","journal-title":"J. Prevent. Med. Hygiene"},{"issue":"11","key":"10.1016\/j.intimp.2021.108351_b0085","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.str.2020.10.001","article-title":"The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by cryo-EM and cryo-ET","volume":"28","author":"Liu","year":"2020","journal-title":"Structure"},{"key":"10.1016\/j.intimp.2021.108351_b0090","article-title":"Antibody response after second-dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) among health care workers in India: final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study","author":"Singh","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.intimp.2021.108351_b0095","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3389\/fimmu.2018.00600","article-title":"Novel platforms for the development of a universal influenza vaccine","volume":"9","author":"Kumar","year":"2018","journal-title":"Front. Immunol."},{"issue":"6499","key":"10.1016\/j.intimp.2021.108351_b0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2021.108351_b0105","article-title":"Neutralization of UK-variant VUI-202012\/01 with COVAXIN vaccinated human serum","author":"Sapkal","year":"2021","journal-title":"BioRxiv"},{"issue":"18","key":"10.1016\/j.intimp.2021.108351_b0110","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.vaccine.2021.03.077","article-title":"The development of COVID-19 vaccines in the United States: why and how so fast?","volume":"39","author":"Kuter","year":"2021","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2021.108351_b0115","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/jcm10071428","article-title":"Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic","volume":"10","author":"Riad","year":"2021","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.108351_b0120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/vaccines9060559","article-title":"Thrombotic thrombocytopenia after COVID-19 vaccination. in search of the underlying mechanism","volume":"9","author":"Rzymski","year":"2021","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.intimp.2021.108351_b0125","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/ph14050406","article-title":"COVID-19 vaccines: a review of the safety and efficacy of current clinical trials","volume":"14","author":"Yan","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.intimp.2021.108351_b0130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijid.2021.07.052","article-title":"Safety and reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Saudi Arabia","volume":"110","author":"Al Bahrani","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2021.108351_b0135","doi-asserted-by":"crossref","unstructured":"P. Cerino, A. Coppola, B. Pierri, P. Volzone, D. Bruzzese, A. Pierri, A. Ferro, D. Schiavi, A. Coppola, S. Miniero, An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2, Future Science OA (0) (2021) FSO739.","DOI":"10.2144\/fsoa-2021-0064"},{"issue":"4","key":"10.1016\/j.intimp.2021.108351_b0140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/diagnostics11040579","article-title":"Mini-review discussing the reliability and efficiency of COVID-19 vaccines","volume":"11","author":"Doroftei","year":"2021","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.intimp.2021.108351_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Medicine"},{"issue":"10255","key":"10.1016\/j.intimp.2021.108351_b0150","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2021.108351_b0155","article-title":"Side effects and immunogenicity following administration of the sputnik V COVID-19 vaccine among health care workers","author":"Babamahmoodi","year":"2021","journal-title":"Observ. Study Iran"},{"key":"10.1016\/j.intimp.2021.108351_b0160","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","author":"Ella","year":"2021","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.intimp.2021.108351_b0165","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1016\/j.mjafi.2021.06.014","article-title":"Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: a prospective observational study","volume":"77","author":"Kamal","year":"2021","journal-title":"Med. J. Armed Forces India"},{"key":"10.1016\/j.intimp.2021.108351_b0170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/JPR.S302115","article-title":"Recommendations and guidance for steroid injection therapy and COVID-19 vaccine administration from the American society of pain and neuroscience (ASPN)","volume":"14","author":"Chakravarthy","year":"2021","journal-title":"J. Pain Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921009875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921009875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:30:00Z","timestamp":1761586200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921009875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"alternative-id":["S1567576921009875"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108351","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108351"}}